Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557166 · ClinicalTrials.gov registry record · Phase 3
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 359
- Enrollment target
NCT01557166 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 359 participants.
The verdict
NCT01557166, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 359 participants
- Enrollment target
Study Summary
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2012-06-07 |
| Est. Completion | 2013-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557166
The ClinicalTrials.gov registry entry for NCT01557166 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01557166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557166 about?
NCT01557166 is a clinical study titled "Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea". This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
What is the current status of trial NCT01557166?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2012-06-07. Estimated completion is 2013-06-17.
What interventions are being tested in trial NCT01557166?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01557166?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.